Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial

    OncoTargets and therapy, Volume 11, 2018, Pages 8575-8587.

    Cited by: 0|Bibtex|Views2|Links
    WOS
    Keywords:
    Chinese patientsEGFRNSCLCPhase IIIafatinibMore(1+)

    Abstract:

    The findings support the rationale for using afatinib as a first-line treatment option for this patient population.

    Code:

    Data:

    Your rating :
    0

     

    Tags
    Comments